Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC

Clinical trial NCT00633529 · COMPLETED

Trial details

NCT number: NCT00633529
Sponsor: EMD Serono
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer

Start date: 2007-11-01
Primary completion: 2010-10-01
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.